Increasingly common in daily practice, this is the first guideline update since 2011, aimed to improve success rates and cut complications.
MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback